Go Pro
→ It’s not about Greenland (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$0.97
-1.5%		$1.71
$0.92
▼
$524.00
$985K0.811.08 million shs283,239 shs
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.09
-7.6%		$1.92
$1.00
▼
$14.64
$3.89M1.821.20 million shs228,365 shs
LianBio stock logo
LIAN
LianBio
$0.05
+37.7%		$0.06
$0.27
▼
$4.99
$5.61M0.231.04 million shs674 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.64
-1.3%		$0.67
$0.57
▼
$2.79
$3.97M4.965.57 million shs227,966 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-1.36%-16.66%-41.41%-71.06%-99.76%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-7.63%-10.66%-40.76%-70.54%-91.77%
LianBio stock logo
LIAN
LianBio
+37.59%+29.68%+34.73%-67.56%-3.59%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-1.29%-10.97%+9.31%-20.38%-57.29%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
$0.97
-1.5%		$1.71
$0.92
▼
$524.00
$985K0.811.08 million shs283,239 shs
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
$1.09
-7.6%		$1.92
$1.00
▼
$14.64
$3.89M1.821.20 million shs228,365 shs
LianBio stock logo
LIAN
LianBio
$0.05
+37.7%		$0.06
$0.27
▼
$4.99
$5.61M0.231.04 million shs674 shs
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$0.64
-1.3%		$0.67
$0.57
▼
$2.79
$3.97M4.965.57 million shs227,966 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-1.36%-16.66%-41.41%-71.06%-99.76%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-7.63%-10.66%-40.76%-70.54%-91.77%
LianBio stock logo
LIAN
LianBio
+37.59%+29.68%+34.73%-67.56%-3.59%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-1.29%-10.97%+9.31%-20.38%-57.29%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
0.00
N/AN/AN/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
2.00
Hold$13.001,092.66% Upside
LianBio stock logo
LIAN
LianBio
0.00
N/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CMND, CVKD, RDHL, and LIAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/3/2026
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/A$14.41 per shareN/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/A$1.17 per shareN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/A$2.71 per shareN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
$290K13.52N/AN/A$0.83 per share0.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
-$3.86M-$139.98N/AN/AN/AN/A-107.50%-70.84%N/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$13.24M-$4.90N/AN/AN/AN/A-406.41%-273.80%11/9/2026 (Estimated)
LianBio stock logo
LIAN
LianBio
-$110.29M-$0.81N/AN/AN/AN/A-33.17%-30.19%N/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
-$430K$900.000.00N/AN/AN/AN/AN/AN/A

Latest CMND, CVKD, RDHL, and LIAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/10/2026Q3 2026
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A-$0.57N/A-$0.57N/AN/A
8/13/2026Q2 2026
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
-$1.42-$1.14+$0.28-$1.14N/AN/A
6/15/2026Q2 2026
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A-$6.78N/A-$6.78N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/AN/AN/AN/AN/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/AN/AN/AN/AN/A
LianBio stock logo
LIAN
LianBio
N/AN/AN/AN/AN/A
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
4.79
4.79
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
N/A
3.73
3.73
LianBio stock logo
LIAN
LianBio
N/A
10.06
10.06
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
N/A
0.34
0.34

Institutional Ownership

CompanyInstitutional Ownership
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
96.05%
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
7.92%
LianBio stock logo
LIAN
LianBio
74.85%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
7.20%

Insider Ownership

CompanyInsider Ownership
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
14.59%
LianBio stock logo
LIAN
LianBio
7.59%
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
6.81%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clearmind Medicine Inc. stock logo
CMND
Clearmind Medicine
N/A1.02 millionN/ANot Optionable
Cadrenal Therapeutics, Inc. stock logo
CVKD
Cadrenal Therapeutics
43.57 million3.05 millionNot Optionable
LianBio stock logo
LIAN
LianBio
110108.06 million99.86 millionNot Optionable
Redhill Biopharma Ltd. stock logo
RDHL
Redhill Biopharma
2106.08 million5.67 millionNo Data

Recent News About These Companies

RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?
September 10 at 10:26 PM  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/redhill-rdhl-acquires-rebyota-clenpiq-160630625.html
Redhill Biopharma (NASDAQ:RDHL) Stock Passes Below 200-Day Moving Average - Should You Sell?
September 9 at 3:41 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31012784
RedHill acquires rights to Ferring’s Rebyota and Clenpiq
September 1, 2026  |  thepharmaletter.comT
Redhill Biopharma stock doubles in one session — here's why
September 1, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/redhill-biopharma-stock-doubles-in-one-session-here-s-why/ar-AA2bhfIt
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring’s Rebyota® and Clenpiq®
September 1, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/currencies/redhill-announces-transformational-acquisition-of-commercialization-rights-to-ferring-s-rebyota-and-clenpiq-1036510879
RedHill divests Talicia business to Apotex
September 1, 2026  |  thepharmaletter.comT
RedHill Announces Transformational Acquisition of Commercialization Rights to Ferring's Rebyota® and Clenpiq®
September 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-announces-transformational-acquisition-of-commercialization-rights-to-ferrings-rebyota-and-clenpiq-302866106.html
RedHill Biopharma Stock Surges 64% Over Deal To Divest Talicia Business
August 31, 2026  |  rttnews.comhttps://www.rttnews.com/3687115/redhill-biopharma-stock-surges-64-over-deal-to-divest-talicia-business.aspx
RedHill Biopharma (NASDAQ: RDHL) Soars to $1.60 - Monetizes Talicia Stake in $18 Million Cash Deal With Apotex
August 31, 2026  |  investorideas.comI
RedHill Divests Talicia® to Apotex for $18 Million Cash Upfront Plus Milestones to Fuel Strategic Growth Opportunities
August 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-divests-talicia-to-apotex-for-18-million-cash-upfront-plus-milestones-to-fuel-strategic-growth-opportunities-302864832.html
Redhill Biopharma Ltd (NASDAQ: RDHL) - Share Price and Research
August 8, 2026  |  intelligentinvestor.com.auI
Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development
July 28, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ebola-cases-and-deaths-rapidly-mount---redhill-updates-on-opaganib-emergency-outbreak-development-302836392.html
RedHill Biopharma Announces Closing of Up To $19.4 Million Private Placement
June 22, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-closing-of-up-to-19-4-million-private-placement-302806815.html
RedHill Biopharma announces up to $19.4M private placement
June 18, 2026  |  msn.comhttps://www.msn.com/en-us/money/companies/redhill-biopharma-announces-up-to-194m-private-placement/ar-AA25Xq2A
RedHill Biopharma Announces Up To $19.4 Million Private Placement
June 18, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-announces-up-to-19-4-million-private-placement-302804327.html
RedHill Biopharma Moves to Advance Opaganib as Oral Antiviral Option for Current Ebola Outbreak
June 13, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/RDHL/pressreleases/2280827/redhill-biopharma-moves-to-advance-opaganib-as-oral-antiviral-option-for-current-ebola-outbreak/
RedHill Biopharma Ltd.: RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
June 9, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68718281-redhill-biopharma-ltd-redhill-s-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-addition-to-current-orphan-drug-design-008.htm
RedHill's Opaganib Receives FDA Rare Pediatric Disease Designation for Neuroblastoma in Addition to Current Orphan Drug Designation
June 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhills-opaganib-receives-fda-rare-pediatric-disease-designation-for-neuroblastoma-in-addition-to-current-orphan-drug-designation-302795146.html
RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo
June 8, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-launches-enforcement-of-11-million-new-york-supreme-court-final-judgment-against-kukbo-302793864.html
RedHill Biopharma Advancing Opaganib Options for Novel Dual Host Directed and Direct Acting Antiviral Approach for Ebola Outbreak Biodefense Platforms
June 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/redhill-biopharma-advancing-opaganib-options-for-novel-dual-host-directed-and-direct-acting-antiviral-approach-for-ebola-outbreak-biodefense-platforms-302788468.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Clearmind Medicine stock logo

Clearmind Medicine NASDAQ:CMND

$0.97 -0.01 (-1.52%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$0.97 +0.00 (+0.24%)
As of 09/11/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Clearmind Medicine Inc., a clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems in Canada and internationally. It develops treatments for alcohol use disorders, mental health disorder, binge drinking, obesity and metabolic disorder, and eating disorders, as well as depression, binge eating, psychotherapy, and other addiction and binge behaviors. The company also develops MEAI compound which is in IND-enabling study for the treatment of alcohol use disorder; and is in pre-clinical study for treatment of obesity, weight loss, metabolic disorder, and addiction. In addition, it has a collaboration with SciSparc Ltd. to conduct a study evaluating the companies combination treatment for obesity and metabolic syndrome; and with Yissum Research Development Company of the Hebrew University of Jerusalem for the discovery and development of novel psychedelic-derived therapeutics to treat mental disorders. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Cadrenal Therapeutics stock logo

Cadrenal Therapeutics NASDAQ:CVKD

$1.09 -0.09 (-7.63%)
Closing price 09/11/2026 04:00 PM Eastern
Extended Trading
$1.08 -0.01 (-0.92%)
As of 09/11/2026 07:09 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

LianBio stock logo

LianBio NASDAQ:LIAN

$0.05 +0.01 (+37.70%)
As of 09/10/2026

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03 for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.

Redhill Biopharma stock logo

Redhill Biopharma NASDAQ:RDHL

$0.64 -0.01 (-1.29%)
Closing price 09/11/2026 03:59 PM Eastern
Extended Trading
$0.61 -0.03 (-4.79%)
As of 09/11/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, advanced unresectable cholangiocarcinoma, prostate cancer, and nuclear radiation protection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 for pulmonary nontuberculous mycobacteria infections caused by mycobacterium avium complex. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas